文献速递乳腺癌

PI3K抑制剂治疗晚期乳腺癌的系统综述与Meta分析

Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis.
PubMed 文献 · Eur J Cancer · 2018-01-11

该系统综述与Meta分析纳入5项随机试验,评估在标准治疗基础上加用PI3K抑制剂治疗晚期乳腺癌的疗效与安全性。结果显示,在未经选择的患者中,加用PI3K抑制剂使疾病进展风险降低21%(HR=0.79,95%CI 0.71-0.88),但任何级别和III级及以上毒性显著增加。基于循环肿瘤DNA分析发现PI3K通路活化的患者获益更明显。

要点

  • 未经选择的晚期乳腺癌患者加用PI3K抑制剂可降低21%的进展风险(HR=0.79)。
  • PI3K抑制剂显著增加任何级别和III级及以上毒性,为剂量限制性因素。
  • 基于ct-DNA检测PI3K通路活化的患者从PI3K抑制剂中获益更明显。

核心结论

  • 在未经选择的晚期乳腺癌患者中,标准治疗加用PI3K抑制剂可降低疾病进展风险,尤其在ct-DNA检测显示PI3K通路活化的患者中更为明显,但显著毒性限制其应用。

研究设计与样本

  • 系统综述与Meta分析,检索Ovid、PubMed、Cochrane Central Register of Controlled Trials和Embase数据库中的相关随机试验,最终纳入5项研究。

主要发现

  • 在未经选择的患者中,加用PI3K抑制剂使进展风险降低21%(2329例参与者,HR=0.79;95%CI 0.71-0.88)。
  • 客观缓解率 marginal 改善(2329例参与者,RR=1.26;95%CI 1.01-1.57),疾病控制率无改善(2146例参与者,RR=1.05;95%CI 0.94-1.18)。
  • 任何级别毒性显著增加(2386例参与者,RR=1.05;95%CI 1.03-1.06),III级及以上毒性显著增加(2386例参与者,RR=1.91;95%CI 1.76-2.08)。
  • 基于肿瘤组织评估的PI3K通路活化与否的患者均可见PFS获益,而基于血浆ct-DNA分析时仅PI3K通路活化的患者可见PFS获益。

关键数值与推荐

  • 未经选择患者PFS的HR=0.79(95%CI 0.71-0.88,2329例参与者)。
  • ORR的RR=1.26(95%CI 1.01-1.57,2329例参与者),DCR的RR=1.05(95%CI 0.94-1.18,2146例参与者)。
  • 任何级别毒性RR=1.05(95%CI 1.03-1.06,2386例参与者),III级及以上毒性RR=1.91(95%CI 1.76-2.08,2386例参与者)。

临床怎么用

  • 在晚期乳腺癌标准治疗基础上加用PI3K抑制剂可改善PFS,但需权衡显著增加的毒性。
  • 基于ct-DNA检测PI3K通路活化的患者可能从PI3K抑制剂治疗中获益更明显。

局限性

  • PI3K抑制剂的显著剂量限制性毒性是临床应用的限制因素。
  • 选择性PI3K抑制剂是否具有更好耐受性和临床角色尚在研究中。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phosphoinositide 3-kinase (PI3K) inhibitors may overcome drug resistance and improve advanced breast cancer (ABC) outcomes. We conducted a systematic review and meta-analysis to assess the efficacy and safety of adding a PI3K inhibitor to the standard of care (SOC) treatment in ABC. The electronic databases Ovid, PubMed, Cochrane Central Register of Controlled Trials and Embase, were searched for relevant randomised trials. Pooled hazard ratios (HRs) for progression-free survival (PFS) and pooled risk ratios (RRs) for objective response rates (ORRs), disease control rates (DCRs) and toxicity were meta-analysed using the Mantel-Haenszel method and generic inverse variance. Five studies were included. In unselected patients, the addition of a PI3K inhibitor decreased the risk of progression by 21% (2329 participants, HR = 0.79; 95% confidence interval [CI], 0.71-0.88). A marginal improvement in ORR (2329 participants, RR = 1.26; 95% CI, 1.01-1.57) and no improvement in DCR (2146 participants, RR = 1.05; 95% CI, 0.94-1.18) were achieved with a significant increase in toxicity of any grade (2386 participants, RR = 1.05; 95% CI, 1.03-1.06) and of grade III and higher (2386 participants, RR = 1.91; 95% CI, 1.76-2.08). A PFS benefit was seen in patients with and without PI3K pathway activation assessed on tumour and only in patients with an activated PI3K pathway when it was assessed from the plasma using circulating tumour DNA (ct-DNA) analysis. The addition of a PI3K inhibitor decreases the risk of progression in unselected ABC patients and particularly in patients with an activated PI3K pathway detected on ct-DNA analysis. However, their significant dose-limiting toxicity is a limiting factor. Selective PI3K inhibitors are being tested to assess whether these better-tolerated agents have a role in ABC treatment.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Raphael J, Desautels D, Pritchard KI, et al. Phosphoinositide 3-kinase inhibitors in advanced breast cancer: A systematic review and meta-analysis. Eur J Cancer. 2018. PMID: 29331750. doi:10.1016/j.ejca.2017.12.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。